Aptevo Reports 93% Clinical Benefit Rate with Mipleta... Triple Combo in TP53-Mutant AML

APVO Aptevo Therapeutics Inc

$1.13 -8.87%

View chart & analysis →

1. 1Aptevo Therapeutics (APVO) reported a 93% clinical benefit rate with a mipleta...-based triple regimen in evaluable patients with first-line TP53-mutant AML.
2. 2Of 14 evaluable patients receiving mipleta..., venetoclax, and azacitidine, 13 (93%) showed clinical benefit, and 11 (79%) achieved CR or CRi, including 9 complete responses.
3. 3The 79% CR/CRi rate compares favorably with the published combined remission rate of 41% for venetoclax plus azacitidine, with remission results nearly doubling that figure.

Source ACCESSWIRE +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →